Controversies in Drug Allergy: Drug Allergy Pathways

Anca M. Chiriac, Aleena Banerji, Rebecca S Gruchalla, Bernard Y.H. Thong, Paige Wickner, Paul Michel Mertes, Ingrid Terreehorst, Kimberly G. Blumenthal

Research output: Contribution to journalReview article

14 Citations (Scopus)

Abstract

Drug allergy pathways are standardized approaches for patients reporting prior drug allergies with the aim of quality improvement and promotion of antibiotic stewardship. At the International Drug Allergy Symposium during the 2018 American Academy of Allergy, Asthma, and Immunology/World Allergy Organization Joint Congress in Orlando, Florida, drug allergy pathways were discussed from international perspectives with a focus on beta-lactam allergy pathways and pragmatic approaches for acute care hospitals. In this expert consensus document, we review current pathways, and detail important considerations in devising, implementing, and evaluating beta-lactam allergy pathways for hospitalized patients. We describe the key patient and institutional factors that must be considered in risk stratification, the central feature of pathway design. We detail shared obstacles to widespread beta-lactam allergy pathway implementation and identify potential solutions to address these challenges.

Original languageEnglish (US)
Pages (from-to)46-60.e4
JournalJournal of Allergy and Clinical Immunology: In Practice
Volume7
Issue number1
DOIs
StatePublished - Jan 1 2019

Fingerprint

Drug Hypersensitivity
beta-Lactams
Hypersensitivity
Internationality
Quality Improvement
Allergy and Immunology
Asthma
Joints
Anti-Bacterial Agents

Keywords

  • Adverse drug reaction
  • Allergy
  • Beta-lactam
  • Drug
  • Graded challenge
  • Guideline
  • Hypersensitivity
  • Penicillin
  • Policy
  • Quality improvement
  • Skin test
  • Stewardship
  • Test dose

ASJC Scopus subject areas

  • Immunology and Allergy

Cite this

Chiriac, A. M., Banerji, A., Gruchalla, R. S., Thong, B. Y. H., Wickner, P., Mertes, P. M., ... Blumenthal, K. G. (2019). Controversies in Drug Allergy: Drug Allergy Pathways. Journal of Allergy and Clinical Immunology: In Practice, 7(1), 46-60.e4. https://doi.org/10.1016/j.jaip.2018.07.037

Controversies in Drug Allergy : Drug Allergy Pathways. / Chiriac, Anca M.; Banerji, Aleena; Gruchalla, Rebecca S; Thong, Bernard Y.H.; Wickner, Paige; Mertes, Paul Michel; Terreehorst, Ingrid; Blumenthal, Kimberly G.

In: Journal of Allergy and Clinical Immunology: In Practice, Vol. 7, No. 1, 01.01.2019, p. 46-60.e4.

Research output: Contribution to journalReview article

Chiriac, AM, Banerji, A, Gruchalla, RS, Thong, BYH, Wickner, P, Mertes, PM, Terreehorst, I & Blumenthal, KG 2019, 'Controversies in Drug Allergy: Drug Allergy Pathways', Journal of Allergy and Clinical Immunology: In Practice, vol. 7, no. 1, pp. 46-60.e4. https://doi.org/10.1016/j.jaip.2018.07.037
Chiriac, Anca M. ; Banerji, Aleena ; Gruchalla, Rebecca S ; Thong, Bernard Y.H. ; Wickner, Paige ; Mertes, Paul Michel ; Terreehorst, Ingrid ; Blumenthal, Kimberly G. / Controversies in Drug Allergy : Drug Allergy Pathways. In: Journal of Allergy and Clinical Immunology: In Practice. 2019 ; Vol. 7, No. 1. pp. 46-60.e4.
@article{9a128dee90ee4721bfb081be9008c9cd,
title = "Controversies in Drug Allergy: Drug Allergy Pathways",
abstract = "Drug allergy pathways are standardized approaches for patients reporting prior drug allergies with the aim of quality improvement and promotion of antibiotic stewardship. At the International Drug Allergy Symposium during the 2018 American Academy of Allergy, Asthma, and Immunology/World Allergy Organization Joint Congress in Orlando, Florida, drug allergy pathways were discussed from international perspectives with a focus on beta-lactam allergy pathways and pragmatic approaches for acute care hospitals. In this expert consensus document, we review current pathways, and detail important considerations in devising, implementing, and evaluating beta-lactam allergy pathways for hospitalized patients. We describe the key patient and institutional factors that must be considered in risk stratification, the central feature of pathway design. We detail shared obstacles to widespread beta-lactam allergy pathway implementation and identify potential solutions to address these challenges.",
keywords = "Adverse drug reaction, Allergy, Beta-lactam, Drug, Graded challenge, Guideline, Hypersensitivity, Penicillin, Policy, Quality improvement, Skin test, Stewardship, Test dose",
author = "Chiriac, {Anca M.} and Aleena Banerji and Gruchalla, {Rebecca S} and Thong, {Bernard Y.H.} and Paige Wickner and Mertes, {Paul Michel} and Ingrid Terreehorst and Blumenthal, {Kimberly G.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.jaip.2018.07.037",
language = "English (US)",
volume = "7",
pages = "46--60.e4",
journal = "Journal of Allergy and Clinical Immunology: In Practice",
issn = "2213-2198",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Controversies in Drug Allergy

T2 - Drug Allergy Pathways

AU - Chiriac, Anca M.

AU - Banerji, Aleena

AU - Gruchalla, Rebecca S

AU - Thong, Bernard Y.H.

AU - Wickner, Paige

AU - Mertes, Paul Michel

AU - Terreehorst, Ingrid

AU - Blumenthal, Kimberly G.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Drug allergy pathways are standardized approaches for patients reporting prior drug allergies with the aim of quality improvement and promotion of antibiotic stewardship. At the International Drug Allergy Symposium during the 2018 American Academy of Allergy, Asthma, and Immunology/World Allergy Organization Joint Congress in Orlando, Florida, drug allergy pathways were discussed from international perspectives with a focus on beta-lactam allergy pathways and pragmatic approaches for acute care hospitals. In this expert consensus document, we review current pathways, and detail important considerations in devising, implementing, and evaluating beta-lactam allergy pathways for hospitalized patients. We describe the key patient and institutional factors that must be considered in risk stratification, the central feature of pathway design. We detail shared obstacles to widespread beta-lactam allergy pathway implementation and identify potential solutions to address these challenges.

AB - Drug allergy pathways are standardized approaches for patients reporting prior drug allergies with the aim of quality improvement and promotion of antibiotic stewardship. At the International Drug Allergy Symposium during the 2018 American Academy of Allergy, Asthma, and Immunology/World Allergy Organization Joint Congress in Orlando, Florida, drug allergy pathways were discussed from international perspectives with a focus on beta-lactam allergy pathways and pragmatic approaches for acute care hospitals. In this expert consensus document, we review current pathways, and detail important considerations in devising, implementing, and evaluating beta-lactam allergy pathways for hospitalized patients. We describe the key patient and institutional factors that must be considered in risk stratification, the central feature of pathway design. We detail shared obstacles to widespread beta-lactam allergy pathway implementation and identify potential solutions to address these challenges.

KW - Adverse drug reaction

KW - Allergy

KW - Beta-lactam

KW - Drug

KW - Graded challenge

KW - Guideline

KW - Hypersensitivity

KW - Penicillin

KW - Policy

KW - Quality improvement

KW - Skin test

KW - Stewardship

KW - Test dose

UR - http://www.scopus.com/inward/record.url?scp=85058940079&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058940079&partnerID=8YFLogxK

U2 - 10.1016/j.jaip.2018.07.037

DO - 10.1016/j.jaip.2018.07.037

M3 - Review article

C2 - 30573422

AN - SCOPUS:85058940079

VL - 7

SP - 46-60.e4

JO - Journal of Allergy and Clinical Immunology: In Practice

JF - Journal of Allergy and Clinical Immunology: In Practice

SN - 2213-2198

IS - 1

ER -